Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Oppilotech, Ltd

OPPILOTECH, LTD.   London, UK
oppilotech.com

OPPILOTECH:CARB-X
TARGETS SYNTHESIS OF LPS

Indirect Therapeutics
Oppilotech is focused on the development of safe antibacterial compounds against drug resistant organisms. This approach entails developing potentiators – agents that can permeabilize the cell envelope allowing the use of established antibacterial compounds. To develop potentiators, Oppilotech has built the most detailed, accurate, computational network model of bacterial cell envelope (LPS, peptidoglycan & phospholipids components) biogenesis that has ever been assembled. The model has allowed Oppilotech to identify a protein involved in the synthesis of LPS found in Gram-negative bacteria that has unique features making it an excellent viable target for drug development. The CARB-X funding allows Oppilotech to undertake early stage experimental analysis of agents that can modulate this target to disrupt the envelope.

Current Development Stage: Hit to Lead

CARB-X Investment: Investment of up to $0.12m

Initial CARB-X Investment Date: April 1, 2017

Graduation Date: October 31, 2017

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023